Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma : a randomized, multicenter, double-blind, placebo-controlled trial

Autor: P. Panzner, Stephen R. Durham, Moises A. Calderon, Ralph Mösges, Mohamed H. Shamji, R. von Frenckell, Marie-Alix Bonny, L. Haazen, Oliver Pfaar, Nathalie Wathelet, Sabine Pirotton, Thierry Legon, Claus Bachert
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Male
Allergy
Lolium perenne
Provocation test
Placebo-controlled study
grass pollen
medicine.disease_cause
Gastroenterology
0302 clinical medicine
Allergen
subcutaneous immunotherapy
QUALITY-OF-LIFE
Medicine and Health Sciences
POLLEN EXPOSURE
Immunology and Allergy
Medicine
Cumulative dose
food and beverages
peptide immunotherapy
clinical trial
Treatment Outcome
PROVOCATION TEST
SAFETY
Pollen
Original Article
Female
Seasons
medicine.medical_specialty
EAACI POSITION PAPER
Immunology
Airway Diseases
QUESTIONNAIRE
Placebo
Poaceae
Drug Administration Schedule
03 medical and health sciences
Internal medicine
Humans
CONJUNCTIVAL
Asthma
business.industry
Rhinitis
Allergic
Seasonal
RHINITIS
Allergens
medicine.disease
EFFICACY
body regions
Clinical trial
030104 developmental biology
030228 respiratory system
Desensitization
Immunologic
Case-Control Studies
Quality of Life
ORIGINAL ARTICLES
business
Peptides
Zdroj: ALLERGY
Allergy
ISSN: 0105-4538
Popis: Background Immunotherapy with peptide hydrolysates from Lolium perenne (LPP) is an alternative treatment for seasonal allergic rhinitis with or without asthma. The aim of this study was to assess the clinical efficacy and safety of a cumulative dose of 170 μg LPP administered subcutaneously over 3 weeks. Methods In a randomized, double blind, placebo-controlled trial, 554 adults with grass pollen rhinoconjunctivitis were randomized (1:2 ratio) to receive 8 subcutaneous injections of placebo or 170 μg LPP administered in increasing doses in 4 visits over 3 weeks. The primary outcome was the combined symptom and medication score (CSMS) measured over the peak pollen season. Reactivity to conjunctival provocation test (CPT) and quality of life (QOL) were assessed as secondary endpoints. Results The mean reduction in CSMS in the LPP vs. placebo group was −15.5% (p=0.041) during the peak period and −17.9% (p= 0.029) over the entire pollen season. LPP treated group had a reduced reactivity to CPT (p
Databáze: OpenAIRE
Externí odkaz: